An editorial published in Frontiers in Biomaterials Science outlines a shifting paradigm in targeted drug delivery, arguing that the field is moving from single-technology solutions toward integrated systems defined by precision and control. These studies collectively illustrate that precision in drug delivery is not achieved through a single technological pathway but through the convergence of nanomedicine, smart biomaterials, protein engineering, and formulation science. The central argument is that meaningful translation of these innovations depends on measurable control, biological relevance, reproducibility, safety, and practical manufacturability, rather than solely on therapeutic efficacy.
The first contribution reviewed is a 2026 analysis by Sureshkumar and Balu, which examines recent preclinical advances in precision nanomedicine. This review covers a wide array of nanocarriers, including lipid-based, polymeric, inorganic, biomimetic, and hybrid systems. A key shift highlighted in this work is the move beyond the traditional distinction between passive and active targeting. Instead, the focus is on achieving spatial, temporal, cellular, and organelle-level control. The authors note that ligand-mediated targeting, stimuli-responsive release, and theranostic functionality are increasingly being integrated into single delivery systems. However, the review emphasizes that greater engineering complexity does not automatically translate to greater clinical benefit.
Several translational realities limit the current potential of nanocarriers. Active targeting is constrained by the availability and accessibility of specific receptors on target cells. Furthermore, subcellular targeting introduces additional biological and manufacturing variables that complicate development. Consequently, the editorial suggests that nanocarriers should be evaluated not only by their therapeutic efficacy but also by their pharmacokinetics, biodistribution, safety, reproducibility, and scalability. The integration of AI-guided design, humanized models, and organ-on-chip platforms is proposed as a method to address these gaps, provided they are supported by robust and standardized datasets.
The second contribution, by Singaravelu et al. in 2026, extends the concept of precision through the examination of smart biomaterials for site-specific and controlled therapeutic delivery. This review explores how natural and synthetic polymers, hydrogels, lipid-polymer hybrids, and organic-inorganic systems can be engineered to respond to specific environmental stimuli. These stimuli include pH, redox state, enzymes, temperature, light, ultrasound, or magnetic fields. Such responsiveness adds a dimension of control that allows the system to determine when and under which biological conditions its payload is released, rather than relying solely on where the carrier accumulates. The value of these systems lies in matching the trigger to a reproducible biological feature.
Despite their potential, smart biomaterials face significant challenges related to disease heterogeneity and formulation complexity. Disease heterogeneity can weaken apparently precise mechanisms, while increasingly complex formulations create additional requirements for characterization and quality control. The review places precision delivery within a broader framework that includes biomarker-guided targeting, standardized nanotoxicology, and computational approaches. This perspective is crucial for moving smart biomaterials from proof-of-concept demonstrations toward clinically meaningful platforms. The editorial notes that the integration of organ-on-chip models and other emerging technologies is essential for this transition, ensuring that the biological relevance of the delivery system is rigorously tested.
A distinct route to precision is presented by Tian et al. in their 2026 examination of elastin-like polypeptides, or ELPs, as programmable carriers for radiopharmaceutical delivery. ELPs offer sequence-defined control over molecular weight, phase-transition behavior, functionalization, and self-assembly. These properties can be coupled with radioiodination, radiometal chelation, and site-specific conjugation to enable thermally triggered or locally retained delivery. In radiopharmaceutical therapy, this level of control is particularly important because carrier behavior directly influences radionuclide biodistribution, tissue retention, and radiation dose deposition. The review illustrates why molecular programmability must be accompanied by rigorous validation to ensure safety and efficacy.
The evidence for ELPs remains heterogeneous across different architectures, radionuclides, administration routes, and disease models. Future development in this area will require systematic assessment of radiochemical stability, in vivo persistence, biodistribution, dosimetry, immunogenicity, and repeat-dose effects. Additionally, manufacturing consistency and regulatory requirements must be addressed to move these systems toward clinical use. The editorial argues that molecular programmability should be viewed as an enabling property rather than a surrogate for demonstrated therapeutic performance. This distinction is critical for maintaining scientific rigor in the development of specialized delivery systems for radiopharmaceuticals.
The fourth contribution, by Randall et al. in 2026, approaches precision from the direction of formulation and route of administration. Their study develops outer membrane vesicle, or OMV, loaded thin films as a potential room-temperature vaccine platform. The study evaluated both vesicle integrity and antigen stability over a period of eight weeks. Several polymer and sugar-alcohol-containing formulations preserved OMV structure, while PEG and glycerol-containing films provided favorable antigen stability. Most formulations also dissolved rapidly in mucosa-mimicking media, supporting the potential for buccal administration. This work broadens the meaning of targeted delivery to include control over storage, dosage form, administration site, and biological accessibility.
For complex biological therapeutics such as OMVs, maintaining structural and antigenic integrity during storage may be as important as optimizing tissue targeting. A stable, accessible formulation can determine whether a sophisticated biological platform is practical outside controlled laboratory settings. The editorial highlights that precision is not limited to molecular recognition but also encompasses the practical aspects of drug delivery. This perspective is particularly relevant for vaccines and other biological agents that may require stringent cold-chain infrastructure, which can limit real-world accessibility. By addressing formulation challenges, researchers can expand the practical utility of biological delivery systems.
Taken together, the four contributions suggest that the next generation of targeted delivery systems should be evaluated across four interconnected dimensions: spatial precision, temporal control, biological specificity, and translational readiness. Nanocarriers provide a versatile framework for multilevel targeting, while smart biomaterials add environmental responsiveness. Programmable proteins offer molecularly encoded control for specialized payloads, and OMV films demonstrate how formulation and administration can expand practical utility. A particularly important lesson is that these dimensions should not be pursued independently. A carrier that reaches the correct tissue but releases its payload prematurely has limited value, and a highly specific ligand is unlikely to compensate for inadequate tissue penetration.
The editorial emphasizes that a programmable biomaterial that cannot be manufactured reproducibly will face substantial barriers to clinical development. Similarly, a biologically effective vaccine platform that requires stringent cold-chain infrastructure may have limited real-world accessibility. Precision therefore emerges from the integration of material design, biological understanding, and practical constraints. The field should move from designing increasingly sophisticated delivery vehicles toward developing delivery systems whose behavior can be predicted, measured, and reproduced. This shift requires the integration of molecular profiling, quantitative imaging, computational modeling, and advanced manufacturing.
Equally important is the early consideration of safety, immunogenicity, batch consistency, storage, scale-up, and regulatory requirements. The four articles in this Research Topic capture this transition well, demonstrating that innovation in targeted drug delivery is no longer defined by a single carrier type or targeting mechanism. Instead, progress is emerging from the convergence of nanotechnology, smart biomaterials, protein engineering, radiopharmaceutical science, and formulation science. The ultimate objective is to deliver the right therapeutic payload to the right biological site, at the right time, and at the right dose. Achieving this objective will require rigorous measurement, interdisciplinary collaboration, and a sustained commitment to translation.
Subject of Research: Editorial: Innovative paths in targeted drug delivery: advances in precision and control
Article Title: Editorial: Innovative paths in targeted drug delivery: advances in precision and control
Article References: Mamidi, N., & Kumar, R. (2026). Innovative Paths in Targeted Drug Delivery: Advances in Precision and Control. Frontiers in Biomaterials Science, 5, 2040082. https://doi.org/10.3389/fbiom.2026.2040082
Image Credits: AI Generated
DOI: 10.3389/fbiom.2026.2040082
Keywords: Editorial, Innovative, paths, targeted, drug, delivery, advances, precision, control
News Source: Louis Brooks. (November 13, 2026). Editorial: Four paths to precision in targeted drug delivery. Scienmag.



